切换至 "中华医学电子期刊资源库"

中华普外科手术学杂志(电子版) ›› 2020, Vol. 14 ›› Issue (01) : 86 -89. doi: 10.3877/cma.j.issn.1674-3946.2020.01.025

所属专题: 文献

论著

LATG联合D2淋巴结清扫在中上部进展期胃癌的手术效果分析
李丽文1, 黄纪媛,1   
  1. 1. 518109 深圳市龙华区人民医院
  • 收稿日期:2019-02-28 出版日期:2020-02-26
  • 通信作者: 黄纪媛

Surgical effect of LATG combined with D2 lymph node dissection in advanced gastric cancer

Liwen Li1, Jiyuan Huang,1   

  1. 1. Shenzhen Longhua District People’s Hospital General Surgery 518109
  • Received:2019-02-28 Published:2020-02-26
  • Corresponding author: Jiyuan Huang
  • About author:
    Corresponding author: Huang Jiyuan, Email:
引用本文:

李丽文, 黄纪媛. LATG联合D2淋巴结清扫在中上部进展期胃癌的手术效果分析[J/OL]. 中华普外科手术学杂志(电子版), 2020, 14(01): 86-89.

Liwen Li, Jiyuan Huang. Surgical effect of LATG combined with D2 lymph node dissection in advanced gastric cancer[J/OL]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2020, 14(01): 86-89.

目的

探讨开腹全胃切除术(OTG)联合D2淋巴结清扫术和腹腔镜全胃切除术(LATG)联合D2淋巴结清扫术在中上部进展期胃癌中的临床应用效果。

方法

回顾性分析2014年1月至2017年6月88例中上部进展期胃癌资料,均行全胃切除术联合D2淋巴结清扫,按手术方式差异分为腹腔镜组(简称LATG组,37例)和开腹组(简称OTG组,51例)。采用SPSS19.0进行统计分析,两组术中术后指标、VAS评分、肿瘤标准物等用(±s)表示,独立t检验;术后无瘤生存率、术后总生存率和术后并发症发生率,行χ2检验,P<0.05为差异有统计学意义。

结果

研究结果显示LATG组手术时间、术中出血量、首次排气时间、首次进食时间、术中切口长度、术后住院时间、并发症总发生率(5.4%比21.6% )、术中相关指标、术后康复指标、术后1周、1个月的VAS评分、术后3个月的CA125、CA199、CEA水平等方面均较OTG组更优(P<0.05)。术中两组的淋巴结清扫数目差异无统计学意义(P>0.05);截止2018年12月,术后1年无瘤生存率和总生存率比较,两组差异无统计学意义(P>0.05)。

结论

LATG联合D2淋巴结清扫术是中上部进展期胃癌临床治疗的较为安全手术手术方法,具有出血量少,切口短小,术后康复快,术后疼痛感低,术后并发症较低的优势。

Objective

To investigate the clinical effect of Open Total Gastrectomy (OTG) combined with D2 lymph node dissection and Laparoscopic total gastrectomy (LATG) combined with D2 lymph node dissection in advanced gastric cancer in the upper and middle part.

Methods

From January 2014 to June 2017, the data of 88 cases of advanced gastric cancer in the upper and middle parts were retrospectively analyzed. Total gastrectomy and D2 lymph node dissection were performed in all patients. According to the different operation, they were divided into Laparoscopic group (LATG group, 37 cases) and open group (OTG group, 51 cases). SPSS19.0 was used for statistical analysis. The intraoperative and postoperative indicators, VAS scores , tumor standard substances were expressed as (±s), and compared with independent t test. After operation, the free survival rate, the total survival rate and the incidence of postoperative complications were compared with χ2 test, P<0.05 was P<0.05 was considered statistically significant.

Result

The results showed that the LATG group had better operative time, intraoperative bleeding volume, first exhaust time, first eating time, intraoperative incision length, post operative hospitalization time, total incidence of complications (5.4% vs. 21.6%), intraoperative related indicators, post operative rehabilitation indicators, VAS scores of 1 week and, 3 month of VAS, CA125, CA199, CEA levels after operation than OTG group (P<0.05). There was no significant difference in the number of lymph node dissections between the two groups (P>0.05). As of December 2018, there was no significant difference in 1 year tumor free survival rate and overall survival rate between the two groups (P>0.05).

Conclusion

LATG combined with D2 lymph node dissection is a safe surgical method for the treatment of advanced gastric cancer in the upper and middle part, It has the advantages of less bleeding, shorter incision, quicker recovery, lower pain and lowwe postoperative complications..

表1 88例中上部进展期胃癌患者不同术式两组一般资料比较[(±s),例]
表2 88例中上部进展期胃癌患者不同术式两组术中术后指标比较(±s)
表3 88例中上部进展期胃癌患者不同术式两组VAS评分比较(±s)
表4 88例中上部进展期胃癌患者不同术式两组术前、术后3个月血清肿瘤标志物比较表(±s)
表5 88例中上部进展期胃癌患者不同术式两组术后并发症及1年生存率比较(例)
[1]
朱晓芸,马如超,于红刚.我国不同手术方式治疗早期胃癌的经济学指标评价[J].中国肿瘤,2019,28 (1):74-80.
[2]
张树朋,梁月祥.进展期远端胃癌行扩大淋巴结清扫术的研究进展[J].中国肿瘤临床,2018,45(21):1104-1108.
[3]
Inoue T, Ikeda Y, Ogawa E,et al.Laparoscopic lysis for jejunostomy related ileus following laparoscopy assisted total gastrectomy: a case report[J].Asian J Endosc Surg,2014,7(2):169-171.
[4]
张全超,孙学军.腹腔镜手术对进展期胃癌患者围术期免疫功能及血凝状态的影响[J].中国肿瘤临床与康复,2018,25(11):1373-1376.
[5]
Inaki N, Etoh T, Ohyama T,et al.A Multi-institutional, Prospective, Phase II Feasibility Study of Laparoscopy-Assisted Distal Gastrectomy with D2 Lymph Node Dissection for Locally Advanced Gastric Cancer ( JLSSG0901) [J].World J Surg,2015,39(11):2734-2741.
[6]
张树朋,梁月祥.进展期远端胃癌行扩大淋巴结清扫术的研究进展[J].中国肿瘤临床,2018,45(21):1104-1108.
[7]
郑晓东,张永智,金鑫,等.胃癌根治术后患者并发胆囊炎的危险因素及预防措施分析[J].中国肿瘤临床与康复,2018,25(7):786-789.
[8]
李森.腹腔镜与开腹远端胃癌根治术治疗进展期胃癌近期疗效Meta分析[D].芜湖:皖南医学院,2016:1-41.
[9]
Huang CM, Wang Y, Wang JB,et al.Laparoscopic Spleen Preserving Splenic Hilar Lymph Node Dissection for Advanced Upper Gastric Cancer in Patients with High Body Mass Index[J].Hepatogastroenterology,2015,62(139):742-747.
[10]
Jung DH, Son SY, Park YS,et al.The learning curve associated with laparoscopic total gastrectomy[J].Gastric Cancer,2016,19(1):264-272.
[11]
李家新,缪刚刚,毛须平.3D腹腔镜在腹腔镜辅助胃癌根治术中的应用价值[J].中国微创外科杂志,2018,18(12):1099-1102.
[12]
余佩武,罗华星.腹腔镜胃癌淋巴结清扫技术[J].临床外科杂志,2013,21(10):750-752.
[13]
余昌文,甘亚平,邹勇.胃癌组织中缺氧诱导因子-1α和葡萄糖转运蛋白-1和下游转录因子1的表达及意义[J].中国肿瘤临床与康复,2018,25(7):781-785.
[14]
钟磊,谢海燕,邱玉梅,等.胃癌应用CA724、CEA、CA242、CA199肿瘤标志物联合检验的分析[J/CD].临床检验杂志(电子版),2019,8(1):116.
[15]
刘轲,金晓波,焦碧英,等.血清肿瘤标志物联合检测对胃癌的诊断价值[J].中国预防医学杂志,2018,19(11):843-846.
[16]
He B, Zhang HQ, Xiong SP,et al.Changing patterns of serum CEA and CA199 for evaluating the response to first line chemotherapy in patients with advanced gastric adeno carcinoma[J].Asian Pac J Cancer Prev,2015,16(8):3111-3116.
[17]
Reglodi D, Illes A, Opper B,et al .Presence and Effects of Pituitary Adenylate Cyclase Activating Polypeptide Under Physiological and Pathological Conditions in the Stomach[J].Front Endocrinol,2018,9:90.
[18]
李子禹,高翔宇,贾永宁.试析腹腔镜胃癌根治术淋巴结清扫的相关问题[J/CD].中华普外科手术学杂志(电子版),2018,12(2):99-102.
[19]
沈韧斌,徐伟.腹腔镜与开腹胃癌根治术对区域淋巴结清扫及并发症的影响比较[J/CD].中华普外科手术学杂志(电子版),2017,11(6):472-474.
[1] 燕速, 霍博文. 腹腔镜食管胃结合部腺癌根治性切除术[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 13-13.
[2] 母德安, 李凯, 张志远, 张伟. 超微创器械辅助单孔腹腔镜下脾部分切除术[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 14-14.
[3] 李国新, 陈新华. 全腹腔镜下全胃切除术食管空肠吻合的临床研究进展[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 1-4.
[4] 李子禹, 卢信星, 李双喜, 陕飞. 食管胃结合部腺癌腹腔镜手术重建方式的选择[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 5-8.
[5] 李乐平, 张荣华, 商亮. 腹腔镜食管胃结合部腺癌根治淋巴结清扫策略[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 9-12.
[6] 陈方鹏, 杨大伟, 金从稳. 腹腔镜近端胃癌切除术联合改良食管胃吻合术重建His角对术后反流性食管炎的效果研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 15-18.
[7] 许杰, 李亚俊, 韩军伟. 两种入路下腹腔镜根治性全胃切除术治疗超重胃癌的效果比较[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 19-22.
[8] 李刘庆, 陈小翔, 吕成余. 全腹腔镜与腹腔镜辅助远端胃癌根治术治疗进展期胃癌的近中期随访比较[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 23-26.
[9] 刘世君, 马杰, 师鲁静. 胃癌完整系膜切除术+标准D2根治术治疗进展期胃癌的近中期随访研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 27-30.
[10] 王庆亮, 党兮, 师凯, 刘波. 腹腔镜联合胆道子镜经胆囊管胆总管探查取石术[J/OL]. 中华肝脏外科手术学电子杂志, 2025, 14(02): 313-313.
[11] 杨建辉, 段文斌, 马忠志, 卿宇豪. 腹腔镜下脾部分切除术[J/OL]. 中华肝脏外科手术学电子杂志, 2025, 14(02): 314-314.
[12] 叶劲松, 刘驳强, 柳胜君, 吴浩然. 腹腔镜肝Ⅶ+Ⅷ段背侧段切除[J/OL]. 中华肝脏外科手术学电子杂志, 2025, 14(02): 315-315.
[13] 郭兵, 王万里, 何凯, 黄汉生. 腹腔镜下肝门部胆管癌根治术[J/OL]. 中华肝脏外科手术学电子杂志, 2025, 14(01): 143-143.
[14] 李凯, 陈淋, 苏怀东, 向涵, 张伟. 超微创器械在改良单孔腹腔镜巨大肝囊肿开窗引流及胆囊切除中的应用[J/OL]. 中华肝脏外科手术学电子杂志, 2025, 14(01): 144-144.
[15] 魏丽霞, 张安澜, 周宝勇, 李明. 腹腔镜下Ⅲb型肝门部胆管癌根治术[J/OL]. 中华肝脏外科手术学电子杂志, 2025, 14(01): 145-145.
阅读次数
全文
0
HTML PDF
最新录用 在线预览 正式出版 最新录用 在线预览 正式出版
0 0 0 0 0 0


摘要
43
最新录用 在线预览 正式出版
0 0 43
  来源 本网站 其他网站
  次数 25 18
  比例 58% 42%